Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial - The Lancet Oncology thelancet.com/journals/lanon…

8⃣Immersive, Interactive Learning with Global Experts Go beyond lectures — #ITCTC25 features case-based discussions, expert Q&As, and audience interaction, ensuring a dynamic and memorable learning experience. ebmt.org/events/10th-in…

Check out how CD19CAR-T for Richters Transformation stacks up in this UK analysis. Broadly safe and effective, ORR 70%, 2y PFS 46%. Risks for poor response- high LDH, non-response bridging, more prior lines. ⁦UCL Cancer Institute⁩⁩ ⁦Satyen Gohil⁩ ⁦ onlinelibrary.wiley.com/doi/10.1111/bj…

🔬 Curious about the role of the microbiome in lymphomas? Join WiLing Wednesdays — July 16, 3pm EST! Dr. Diefenbach & Dr. Paola Ghione MD, MSEpi will dive into it all. 🧬 Free & open to all! 🔗 Register now: us06web.zoom.us/webinar/regist… #WomenInLymphoma #Lymphoma #Microbiome

9⃣Ready to shape the future?🚀 Join us at #ITCTC25 — where leaders grow🔥 📸Past committee, forever proud. 💬Be heard. Be bold. ebmt.org/events/10th-in…

Really privileged to have met all this wonderful colleagues!. Do not miss the great opportunity to attend #ITCTC25

Do infectious agents drive lymphoma initiation? Find out next week during the 3rd webinar of the Pathogens and Lymphoma Series with Catharine Thieblemont, Ayako Arai, Amira Marouf, Florence Broussais-Guillaumot and Soni Smith MD Register ➡️ us06web.zoom.us/webinar/regist…

Our group's latest publication demonstrates the correlation between PET/CT-derived body composition and outcome in DLBCL. #DeepLearning #lymsm #lymphoma Sylvester Comprehensive Cancer Center CRANE Lab Craig Moskowitz, MD UMiami Health System ascopubs.org/doi/10.1200/CC…

#destacadoSEHH | El curso de terapias avanzadas de la UMU refuerza el papel clínico de la investigación académica immedicohospitalario.es/noticia/52199/… a través de IM Médico

Muy orgullosas de nuestras residentes, ahora adjuntas!!! 👩🏻‍🎓 Ares Guardia te deseamos lo mejor en esta nueva etapa!!👏🏼🎉🎉 Caminar

Interesting interview to Eva Domingo-Domenech Institut Català d'Oncologia and others… in Spanish media, highlighting new developments in precision oncology and clinical trials impacting on hematological cancer patients care 👏 👏 👏!

Nuevo estudio del grupo de complicaciones infecciosas del GETH. Papel del tiempo de duplicación en la era Letermovir. onlinelibrary.wiley.com/doi/10.1111/ti…

#MIR21 Felicidades a todos los #HematoRulers que terminan hoy su residencia! Muy merecido! A disfrutar esta nueva etapa del camino, seguiremos just creciendo y aprendiendo! #HematoMola!

Do infectious agents drive lymphoma initiation? 🦠 Join us ! 3rd webinar in Pathogens & Lymphoma series with global experts: 🔹 Catherine Thieblemont - Ayako Arai 🔹 Florence Broussais, Amira Marouf, Somali Smith 🗓 July 23, 2025 – 4PM EST Register now:lnkd.in/gVEZGcRB

A potential mechanistic explanation of the beneficial role of aHSCT in Multiple Sclerosis. rdcu.be/ewW7W

📣 Finally out!! Reduced doses of PTCy (60mg/kg total dose) combined with tacrolimus preserves key clinical outcomes while potentially reducing acute hematological and infectious toxicity. doi.org/10.1111/ejh.70…

Congratulations marivi mateos and Elena Zamagni!! So well deserved 👏👏👏👏 -#mmsm

📝 A presentation by Julie Vose during the Lymphoma Hub symposium at #18ICML highlighted the current unmet needs for the treatment of patients with MCL. Learn more: loom.ly/zhVtS3s #Lymphoma #lymsm #MedEd

🎉𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗣𝗿𝗼𝗳. 𝗠𝗮𝗿𝗶́𝗮-𝗩𝗶𝗰𝘁𝗼𝗿𝗶𝗮 𝗠𝗮𝘁𝗲𝗼𝘀 𝘚𝘩𝘦 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘢𝘸𝘢𝘳𝘥𝘦𝘥 𝘵𝘩𝘦 𝗪𝗮𝗹𝗱𝗲𝗻𝘀𝘁𝗿𝗼̈𝗺 𝗟𝗶𝗳𝗲𝘁𝗶𝗺𝗲 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁 𝗔𝘄𝗮𝗿𝗱 𝘛𝘩𝘪𝘴 𝘢𝘸𝘢𝘳𝘥 𝘪𝘴 𝘨𝘪𝘷𝘦𝘯 𝘵𝘰 𝘢 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩𝘦𝘳

HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…